About Us
About Boji
One-Stop Full-Process CRO+CDMO Service Provider for Innovative Drugs and Medical Devices
About Boji
About Us
Boji Medical Technology Co., Ltd.(referred to as “BojiMed,” stock code: 300404) was established in 2002 and listed on the Shenzhen ChiNext Board in 2015. With a registered capital of RMB 382 million, it is a new high-tech enterprise providing comprehensive “one-stop” outsourcing services (CRO+CDMO) for drug and medical device R&D and manufacturing to domestic and international pharmaceutical companies.
The company operates from 120,000 square meters of modern office, laboratory, and production facilities, currently employing over 1,400 staff. It owns more than 30 wholly-owned and controlled subsidiaries, along with over a dozen equity-participated companies engaged in related businesses. It has earned numerous honors including: Top 10 Pharmaceutical Outsourcing Companies in China, Top 10 Most Competitive Pharmaceutical Service Enterprises in China, National Specialized, Sophisticated, Distinctive, and Innovative “Little Giant” Enterprise, Guangdong Provincial Enterprise Technology Center, Guangdong Provincial Postdoctoral Innovation Practice Base, China's Top 50 Most Investment-Worthy Enterprises, and Honorary Chair Unit of the CRO Branch of the China Pharmaceutical Quality Management Association. As a leading full-service CRO in China, it is also the first publicly listed CRO primarily focused on clinical trials.
BojiMed's “one-stop” services encompass: new drug project initiation and active compound screening; pharmaceutical research (API, formulations); drug evaluation (pharmacodynamics, toxicology); integrated small molecule innovation drug services; clinical research (including medical devices); dual China-US drug/device registration services (regulatory submissions); CDMO manufacturing (MAH implementation); and technology commercialization—covering all stages of new drug development.
Contact Number: 020-38473208
Collaboration Email: bd03@gzboji.com
The company operates from 120,000 square meters of modern office, laboratory, and production facilities, currently employing over 1,400 staff. It owns more than 30 wholly-owned and controlled subsidiaries, along with over a dozen equity-participated companies engaged in related businesses. It has earned numerous honors including: Top 10 Pharmaceutical Outsourcing Companies in China, Top 10 Most Competitive Pharmaceutical Service Enterprises in China, National Specialized, Sophisticated, Distinctive, and Innovative “Little Giant” Enterprise, Guangdong Provincial Enterprise Technology Center, Guangdong Provincial Postdoctoral Innovation Practice Base, China's Top 50 Most Investment-Worthy Enterprises, and Honorary Chair Unit of the CRO Branch of the China Pharmaceutical Quality Management Association. As a leading full-service CRO in China, it is also the first publicly listed CRO primarily focused on clinical trials.
BojiMed's “one-stop” services encompass: new drug project initiation and active compound screening; pharmaceutical research (API, formulations); drug evaluation (pharmacodynamics, toxicology); integrated small molecule innovation drug services; clinical research (including medical devices); dual China-US drug/device registration services (regulatory submissions); CDMO manufacturing (MAH implementation); and technology commercialization—covering all stages of new drug development.
Contact Number: 020-38473208
Collaboration Email: bd03@gzboji.com
创新药械一站式
全流程CRO+CDMO服务商
Development History
2002 year
Company Incorporation
2005 year
Beijing Branch Established
2009 year
Pharmaceutical Research Center Moves into Pazhou Laboratory
2010 year
Introducing strategic investment from Dachen Venture Capital
2011 year
Deepening Domestic Roots Localized Expansion
Acquired a 12,000-square-meter laboratory building to expand preclinical operations;
Established a Shanghai subsidiary;
Completed the conversion to a joint-stock company.
Established a Shanghai subsidiary;
Completed the conversion to a joint-stock company.
2012 year
File for an IPO, implement shareholding system reform
2015 year
Listing on the stock exchange
2016 year
Establish a medical device clinical company
2017 year
Dual Reporting in China and the U.S. Moving Toward the International Stage
Acquired U.S.-based HPC to develop dual-reporting services in China and the U.S.;
Established Bohui Kang (renamed Boji Data in 2023) to develop data statistics services.
Established Bohui Kang (renamed Boji Data in 2023) to develop data statistics services.
2018 year
Obtain GLP certification
Obtained GLP certification; Obtained a drug manufacturing license; The integrated layout is essentially complete.
2019 year
Establish an Integrated Service Center for Innovative Drugs
2020 year
Shenzhen Borui was established.
2021 year
Raised 340 million yuan in refinancing
2022 year
Boji Technology Park Topped Out
2023 year
Based in North America, expanding globally
Subsidiary BIOTrialMed officially commenced operations.
2024 year
Contract value exceeds 1.5 billion
2025 year
Winning the Future
Our Advantage
Highly experienced
BOJIMED has been deeply rooted in the CRO industry for 23 years and celebrated its 10th anniversary as a listed company on the A-share market. As one of China's earliest CRO service providers, it boasts extensive project experience, concentrated industry resources, precise service solutions, and a comprehensive quality system.
Quality First
Since its establishment, BOJIMED has successfully completed all clinical projects reviewed by the National Medical Products Administration. The company maintains seamless coordination across all departments, prioritizes quality, ensures efficient communication, and guarantees project timelines.
Global footprint
BOJIMED has established a global presence with subsidiaries in mainland China, Hong Kong, China, and Maryland, USA. We are well-versed in regulatory requirements for registration and clinical trials in Europe, the Americas, and Asia-Pacific countries, enabling us to provide comprehensive global clinical services.
Team Strengths
BOJIMED boasts numerous experts with national-level regulatory review backgrounds. Its core team maintains direct communication channels with the FDA, CDE, and leading principal investigators in the industry, fostering strong collaborative relationships that enable project advancement across multiple levels. With a dedicated Study Start-Up team of nearly 100 professionals, the company demonstrates significant advantages in driving preliminary launch activities—including site selection, site processes, and site initiation—ensuring seamless integration between regulatory and clinical work to accelerate product clinical development timelines.
Corporate Culture
Corporate Philosophy
Honest and trustworthy,professional authority,make progress with Customers.
Corporate Vision
Build a professional, honest, enterprising and harmonious Boji family.
Corporate Values
Professionalism, Integrity, Initiative, Collaboration; Building a Harmonious Family Together.
Corporate Spirit
Integrity and trustworthiness, professionalism and authority.
Business Philosophy
Think for customers, serve customers and make progress together with customers.
Management Concept
Service is fundamental, quality is life.